{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-027680","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.666832+00:00","generated_at":"2026-05-16T13:12:35.391431+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Processa Pharmaceuticals announces 1-for-25 reverse stock split effective Dec 16, 2025","bullets":["Reverse split reduces outstanding shares 25:1; no change to authorized shares (1B).","Effective 5:00 p.m. ET Dec 16, 2025; split-adjusted trading begins Dec 17, 2025 under symbol PCSA.","New CUSIP number 74275C403; fractional shares rounded up to nearest whole share.","Outstanding options, warrants, and RSUs adjusted proportionally per their terms.","Stockholders' ownership percentages unchanged except for fractional share rounding."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-027680","json":"https://secwatch.observer/filing/0001493152-25-027680.json","markdown":"https://secwatch.observer/filing/0001493152-25-027680.md","text":"https://secwatch.observer/filing/0001493152-25-027680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315225027680/0001493152-25-027680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315225027680/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:12:35.391431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6648022a94ffd043adcfaacc4b6998f694bacaa","claim":"Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2025-12-16).","evidence_excerpt":"On December 12, 2025, Processa Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), effective as of 5:00 p.m. Eastern Time on December 16, 2025.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315225027680/0001493152-25-027680-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-12-16"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}